Physician profile
Earnest N Williams
NPI 1891435798
$1,450.24
in general payments reported to CMS, 2019-2025
15 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $180 · 2023: $646 · 2024: $326 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $289.53 | 2023-2024 | Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.49 | 2023 | |
| Sumitomo Pharma America, INC. | $203.16 | 2023-2024 | Aptiom, Gemtesa |
| Jazz Pharmaceuticals INC. | $150.00 | 2025 | |
| Dexcom, INC. | $129.17 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| E.R. Squibb & Sons, L.L.C. | $120.83 | 2022 | |
| Glaxosmithkline, LLC. | $107.10 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $97.77 | 2024 | Rexulti |
| Lundbeck LLC | $21.73 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.59 | 2022 | |
| Inogen, INC. | $20.07 | 2022 | |
| Lilly USA, LLC | $19.59 | 2023 | Mounjaro |
| Rgh Enterprises LLC | $19.19 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.62 | 2022 | |
| Ucb, INC. | $13.40 | 2023 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earnest Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.